REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-03. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
=== Nervous system involvement === The original clinical criteria of MCTD stressed the absence of central nervous system (CNS) involvement. For instance, people with MCTD do not suffer serious problems such as cerebritis, psychosis, or seizures. However, roughly 25% of individuals have some form of CNS illness. The most common central nervous system manifestation is trigeminal (fifth cranial) nerve neuropathy, which may be a patient’s first symptom. Headaches are prevalent and are typically vascular in origin. Headaches can also be due to aseptic meningitis. Sensorineural hearing loss is frequently overlooked; however, it is estimated to occur in 50% of MCTD patients.
On December 31, 2020, Pritzker announced the expungement of approximately 500,000 non-felony cannabis-related arrest records. On February 22, 2021, Pritzker signed a criminal justice reform bill that, among other things, makes Illinois the first U.S. state to eliminate cash bail. The provision was scheduled to go into effect in January 2023, but was put on hold, pending the Illinois Supreme Court's review. In July 2023, the Illinois Supreme Court ruled that the elimination of cash bail was constitutional and would go into effect in September 2023.
Major Fishback's courageous letter shed light on the atrocities that were being committed—shamefully—in the name of our nation. ... After reports emerged from horrific abuses at Abu Ghraib in Iraq, I tried for a year and a half to pass legislation to make it clear that cruel, inhuman, and degrading treatment of detainees was illegal. Two military heroes, my former colleague Senator John McCain and Major Fishback, turned the tide in this effort.
Sources: en.wikipedia.org
=== Australia === Nando's has been in continuous operation within Australia since 1990, when the first restaurant opened in Tuart Hill in Western Australia. As of August 2021, there were 155 restaurants in Australia; 63 in Victoria, 36 in Western Australia, 30 in Queensland, 16 in New South Wales, four in South Australia, two in the Northern Territory, three in Tasmania and two in the Australian Capital Territory. Per city, there are 59 in Melbourne, 34 in Perth, 20 in Brisbane, 15 in Sydney, four each in Adelaide and the Gold Coast, three in Ipswich, two each in Hobart, Canberra and Darwin and one each in Ballarat, Bunbury, Geelong, Kalgoorlie, Launceston, Newcastle, Rockhampton, Shepparton, the Sunshine Coast, Townsville and Traralgon. There have been various public battles between the parent company and its Australian franchisees.
==== Animal models ==== The safety of adjuvants are often tested using animal models. Model animals are given a dose of the adjuvant (sometimes comparable to real human/animal vaccines, sometimes higher) by injection, at a site that may or may not be analogous to real-life use. For example, aluminium adjuvants can kill motor neurons when subcutaneously injected at the scruff of a mouse's neck; oil–water suspensions such as pristane produces a precursor to lupus when given to mice by intraperitoneal injection; and arthritis-prone rat strains develop rheumatoid arthritis when injected with 0.2–0.3 mL squalene at the tail. All three examples above concern the classical "grandfathered" adjuvants: if a new adjuvant candidate shows these ill effects in animal testing, it would likely not be further developed, let alone becoming widely used. But more importantly, no effect similar to the above has been found in humans during the decades of their use (including among people genetically predisposed to autoimmunity), showing that animal models are not perfect models – nothing can be a perfect model of another thing, after all.
== Career == Letby began working as a registered nurse in the neonatal unit at the Countess of Chester Hospital on 2 January 2012. In 2012 and 2013 she took part in a fundraising campaign for a new neonatal unit. Colleagues later recalled that she sometimes described non‑intensive care work as boring. She completed another specialisation course in March 2014 and had a second placement at Liverpool Women's Hospital in early 2015. In July 2013, Letby set a morphine infusion rate incorrectly, leading the deputy ward manager to suspend her from administering controlled drugs and require additional training. The suspension was lifted a week later after she raised the matter with the unit manager. In April 2016, she administered antibiotics that had not been prescribed, which she described as a minor error, and she was subsequently moved from night shifts to day shifts. In June 2016, consultant paediatrician and neonatal-unit lead clinician Stephen Brearey asked hospital management to remove Letby from clinical duties pending an investigation. She was transferred to the patient experience team the following month and later to the risk and patient safety office, where she remained until her arrest in 2018. After an interim suspension in 2020, the Nursing and Midwifery Council struck off Letby's registration on 12 December 2023 after her conviction. Letby had informed the council that she did not accept guilt but would not contest her removal.
(WINNER) The contestant won the whole competition. (WIN) The contestant won the Haunted Heat (HIGH) The contestant had one of the best dishes in the Haunted Heat. (IN) The contestant performed well enough to move on to the next week. (RISK) The contestant had one of the bottom dishes in the Haunted Heat and competed in the Bake for Your Life challenge, but was not eliminated. (LOW) The contestant had one of the bottom dishes in the episode's only challenge but was not eliminated. (OUT) The contestant was eliminated for worst dish. (WDR) The contestant withdrew from the competition.
Sources: en.wikipedia.org
The AZFc subregion is located in the distal part of Yq11. Genes in this region have a diverse role, but overall, they are essential to complete spermatogenesis. AZFc deletions have been associated with drastic reduction in sperm count, and there are subsets of men with AZFc microdeletions that experience progressive declines in their sperm count. There are multiple candidate genes in the AZFc region that have been shown to cause infertility in males: Deleted in Azoospermia (DAZ), Chromodomain Protein, Y-linked (CDY), and Basic Protein, Y-linked, 2 (BPY2). AZFc is one of the most genetically dynamic regions in the human genome, possibly serving as counter against the genetic degeneracy associated with the lack of a partner chromosome during meiosis. However, such strategy comes has the adverse effects that some rearrangements represent a risk factor or a de facto causative agent of spermatogenic disruption. A specific partial deletion of AZFc called gr/gr deletion is significantly associated with male infertility among Caucasians in Europe and the Western Pacific region.
It is on the World Health Organization's List of Essential Medicines for its obstetric uses. Lubiprostone is a PGE1 derivative used to treat chronic constipation. It is taken orally. Common side effects include diarrhea, vomiting, and abdominal pain.
=== 1968 === January 30: Tet Offensive in South Vietnam begins. March 1: The years of Lead start in Italy with the Battle of Valle Giulia clash between far-right and far-left militants. March 12: Mauritius becomes independent from the UK under Commonwealth status. March 18: The Moro conflict begins in Southern Philippines. March 30: Johnson suspends bombings over North Vietnam and announces he is not running for reelection. June 8: Tet Offensive ends; while an American military victory, it raises questions over America's military chances in Vietnam. June 17: The Second Malayan Emergency begins. July 1: The Treaty on the Non-Proliferation of Nuclear Weapons (NPT) is opened for signature. July 17: Abdul Rahman Arif, the President of Iraq at that time was overthrown by a coup staged by Iraq Ba'athist Party. The revolution eventually lead to the installation of the Ba'athist government in Iraq. August 20: Prague Spring Reforms in Communist Czechoslovakia result in Warsaw Pact, led by Soviet Red Army, crushing Czechoslovak revolt. September 6: Swaziland becomes independent from the UK. October 3: Peruvian General Juan Velasco Alvarado overthrows President Fernando Belaunde Terry in a military coup. October 12: Spanish Guinea (modern day Equatorial Guinea) becomes independent from Spain. December 23: The captain and crew of the USS Pueblo are released by North Korea. December 21–27: The launch of Apollo 8, the first crewed spaceflight to enter the gravitational influence of another celestial body and to orbit the Moon.
Heat or ionizing irradiation can be used to kill the bacteria that cause decomposition. Heat is applied by cooking, blanching or microwave heating in a manner that pasteurizes or sterilizes fish products. Cooking or pasteurizing does not completely inactivate microorganisms and may need to be followed with refrigeration to preserve fish products and increase their shelf life. Sterilised products are stable at ambient temperatures up to 40 °C, but to ensure they remain sterilized they need packaging in metal cans or retortable pouches before the heat treatment.
DKA is common in type 1 diabetes as this form of diabetes is associated with an absolute lack of insulin production by the islets of Langerhans. In type 2 diabetes, insulin production is present but is insufficient to meet the body's requirements as a result of end-organ insulin resistance. Usually, these amounts of insulin are sufficient to suppress ketogenesis. If DKA occurs in someone with type 2 diabetes, their condition is called "ketosis-prone type 2 diabetes". The exact mechanism for this phenomenon is unclear, but there is evidence both of impaired insulin secretion and insulin action. Once the condition has been treated, insulin production resumes and often the person may be able to resume diet or tablet treatment as normally recommended in type 2 diabetes. The clinical state of DKA is associated, in addition to the above, with the release of various counterregulatory hormones such as glucagon and adrenaline, as well as cytokines, the latter of which leads to increased markers of inflammation, even in the absence of infection. Cerebral edema, which is the most dangerous DKA complication, is probably the result of a number of factors. Some authorities suggest that it is the result of overvigorous fluid replacement, but the complication may develop before treatment has been commenced. It is more likely in those with more severe DKA, and in the first episode of DKA.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.